SCNLF (Scancell Holdings) EPS without NRI: $-0.01 (TTM As of Oct. 2025)


SCNLF Scancell Holdings PLC SCNLF
20 GF Score
Price $0.28
! 2 Warning Signs
View Full Analysis

What is Scancell Holdings EPS without NRI?

Scancell Holdings SCNLF 20 EPS without NRI is $-0.01 as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 1,171 Biotechnology companies, Scancell Holdings ranks worse than 85397.01% on this metric.

Scancell Holdings's earnings per share without non-recurring items for the six months ended in Oct. 2025 was $-0.01. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Oct. 2025 was $-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Scancell Holdings's EPS without NRI or its related term are showing as below:

SCNLF's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.8
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Scancell Holdings's EPS (Diluted) for the six months ended in Oct. 2025 was $-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Oct. 2025 was $-0.01.

Scancell Holdings's EPS (Basic) for the six months ended in Oct. 2025 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Oct. 2025 was $-0.01.


Scancell Holdings  (OTCPK:SCNLF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Scancell Holdings EPS without NRI Related Terms


Scancell Holdings EPS without NRI Historical Data

* Premium members only.

The historical data trend for Scancell Holdings's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings EPS without NRI Chart

Scancell Holdings Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.02 -0.02 -0.03 -0.02

Scancell Holdings Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.00 -0.01

SCNLF vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Scancell Holdings's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's PE Ratio without NRI falls into.


SCNLF
20GF Score
Scancell Holdings PLC SCNLF
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scancell Holdings EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Oct. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-0.01 mean?
Scancell Holdings (SCNLF) has a EPS without NRI of $-0.01 as of Oct. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Scancell Holdings and its competitors. According to the industry distribution chart, Scancell Holdings ranks #999999 out of 1171 companies in the Biotechnology industry.
Is Scancell Holdings' EPS without NRI too high?
Scancell Holdings' current EPS without NRI is $-0.01. Based on the distribution chart, Scancell Holdings ranks #999999 out of 1171 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #999999 out of 1171 companies for EPS without NRI. This places Scancell Holdings in the lower half of its industry. The industry median EPS without NRI is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,171 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Scancell Holdings and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scancell Holdings's current EPS without NRI is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current EPS without NRI of $-0.01. The current EPS without NRI is $-0.01. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current EPS without NRI is $-0.01 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scancell Holdings Business Description

Other Exchanges SCLP:UKSCP:Germany
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
20GF Score

Get the complete analysis for SCNLF

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price